medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2018, Number 3

<< Back Next >>

Rev Invest Clin 2018; 70 (3)

Epidemiological Profile, Gastrointestinal Toxicity, and Treatment of Pelvic Cancers in Patients Managed with Radiotherapy to the Abdominal Pelvic Area

Cetina-Pérez L, Serrano-Olvera A, Flores-Cisneros L, Jiménez-Lima R, Alvarado-Silva C, Díaz-Romero MC, Morales-Vásquez F, Muñoz-González DE, Mota-García A, Chávez-Fierro OA, Jaramillo-Manzur SC, de la Garza-Salazar J, Castro-Eguiluz D, Meneses-García A

Language: English
References: 39
Page: 112-116
PDF size: 67.67 Kb.


ABSTRACT

Mexico has seen an increase in cancer prevalence in its entire population as well as particular age ranges, predominantly the older segment. The most frequently reported pelvic cancers in Mexico are cervical, endometrial, bladder, prostate, rectum, and anal canal. Approximately 80% of the population diagnosed with pelvic cancers present with locally advanced tumors and require concomitant chemoradiotherapy, sequential chemoradiotherapy, or radiotherapy alone. The toxicity of any of these treatment modalities may be manifested as intestinal injury, a significant problem that can compromise the response to treatment, the patient’s nutritional state, quality of life, and survival. In this article, we will approach key aspects in nutrition as well as the epidemiological characteristics and toxicities in patients affected by these pelvic tumors.


REFERENCES

  1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359-86.

  2. Ríos PR, Rivera AG, Cervantes FS, Martínez PM. Tendencia de la mortalidad por cáncer en México: 1990-2012. Evid Méd Invest Salud. 2015;8:5-15.

  3. Netter FH. Atlas of Human Anatomy. Professional Edition. 5th ed. Philadelphia: Saunders; 2010.

  4. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: cervical Cancer.V 1.2016. J Natl Compr Canc Netw. 2016;64:???.

  5. Gandhi AK, Sharma DN, Rath GK, et al. Early clinical outcomes and toxicity of intensity modulated versus conventional pelvic radiation therapy for locally advanced cervix carcinoma: a prospective randomized study. Int J Radiat Oncol Biol Phys. 2013; 87:542-8.

  6. Viswanathan AN, Yorke ED, Marks LB, Eifel PJ, Shipley WU. Radiation dose-volume effects of the urinary bladder. Int J Radiat Oncol Biol Phys. 2010;76:S116-22.

  7. Teo MT, Sebag-Montefiore D, Donnellan CF. Prevention and management of radiation-induced late gastrointestinal toxicity. Clin Oncol (R Coll Radiol). 2015;27:656-67.

  8. Susko M, Craciunescu O, Meltsner S, et al. Vaginal dose is associated with toxicity in image guided tandem ring or ovoidbased brachytherapy. Int J Radiat Oncol Biol Phys. 2016; 94:1099-105.

  9. Gondi V, Bentzen SM, Sklenar KL, et al. Severe late toxicities following concomitant chemoradiotherapy compared to radiotherapy alone in cervical cancer: an inter-era analysis. Int J Radiat Oncol Biol Phys. 2012;84:973-82.

  10. van de Wetering FT, Verleye L, Andreyev HJ, et al. Non-surgical interventions for late rectal problems (proctopathy) of radiotherapy in people who have received radiotherapy to the pelvis. Cochrane Database Syst Rev. 2016;4:CD003455.

  11. Nout RA, Putter H, Jürgenliemk-Schulz IM, et al. Five-year quality of life of endometrial cancer patients treated in the randomised post operative radiation therapy in endometrial cancer (PORTEC-2) trial and comparison with norm data. Eur J Cancer. 2012;48:1638-48.

  12. Andreyev HJ, Wotherspoon A, Denham JW, Hauer-Jensen M. Defining pelvic-radiation disease for the survivorship era. Lancet Oncol. 2010;11:310-2.

  13. Denham JW, Hauer-Jensen M, Peters LJ. Is it time for a new formalism to categorize normal tissue radiation injury? Int J Radiat Oncol Biol Phys. 2001;50:1105-6.

  14. Khalid U, McGough C, Hackett C, et al. A modified inflammatory bowel disease questionnaire and the vaizey incontinence questionnaire are more sensitive measures of acute gastrointestinal toxicity during pelvic radiotherapy than RTOG grading. Int J Radiat Oncol Biol Phys. 2006;64:1432-41.

  15. MacNaughton WK. Review article: new insights into the pathogenesis of radiation-induced intestinal dysfunction. Aliment Pharmacol Ther. 2000;14:523-8.

  16. Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol. 2010;28:573-621.

  17. Wedlake L, Slack N, Andreyev HJ, Whelan K. Fiber in the treatment and maintenance of inflammatory bowel disease: a systematic review of randomized controlled trials. Inflamm Bowel Dis. 2014;20:576-86.

  18. National Institute of Cancer. Common Terminology Criteria for Adverse Events ( CTCAE ), Version 4.0, DCTD, CTI, NIH, DHHS.; 2009.

  19. Maduro JH, Pras E, Willemse PH, de Vries EG. Acute and longterm toxicity following radiotherapy alone or in combination with chemotherapy for locally advanced cervical cancer. Cancer Treat Rev. 2003;29:471-88.

  20. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the radiation therapy oncology group (RTOG) and the european organization for research and treatment of cancer (EORTC) Int J Radiat Oncol Biol Phys. 1995;31:1341-6.

  21. Jones JW, Tudor G, Li F, et al. Citrulline as a biomarker in the murine total-body irradiation model: correlation of circulating and tissue citrulline to small intestine epithelial histopathology. Health Phys. 2015;109:452-65.

  22. Lutgens LC, Deutz NE, Gueulette J, et al. Citrulline: a physiologic marker enabling quantitation and monitoring of epithelial radiation-induced small bowel damage. Int J Radiat Oncol Biol Phys. 2003;57:1067-74.

  23. Papadia C, Sherwood RA, Kalantzis C, et al. Plasma citrulline concentration: a reliable marker of small bowel absorptive capacity independent of intestinal inflammation. Am J Gastroenterol. 2007;102:1474-82.

  24. Lutgens L, Lambin P. Biomarkers for radiation-induced small bowel epithelial damage: an emerging role for plasma citrulline. World J Gastroenterol. 2007;13:3033-42.

  25. Limburg PJ, Ahlquist DA, Sandborn WJ, et al. Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. Am J Gastroenterol. 2000;95:2831-7.

  26. Indaram AV, Visvalingam V, Locke M, Bank S. Mucosal cytokine production in radiation-induced proctosigmoiditis compared with inflammatory bowel disease. Am J Gastroenterol. 2000; 95:1221-5.

  27. Jereczek-Fossa BA, Jassem J, Badzio A. Relationship between acute and late normal tissue injury after postoperative radiotherapy in endometrial cancer. Int J Radiat Oncol Biol Phys. 2002;52:476-82.

  28. Heemsbergen WD, Peeters ST, Koper PC, Hoogeman MS, Lebesque JV. Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage. Int J Radiat Oncol Biol Phys. 2006;66:3-10.

  29. Xu B, Guo Y, Chen Y, et al. Is the irradiated small bowel volume still a predictor for acute lower gastrointestinal toxicity during preoperative concurrent chemo-radiotherapy for rectal cancer when using intensity-modulated radiation therapy? Radiat Oncol. 2015;10:257.

  30. Demirer S, Aydintug S, Aslim B, et al. Effects of probiotics on radiation-induced intestinal injury in rats. Nutrition. 2006;22: 179-86.

  31. Tirado L, Mohar A. Epidemiología del Cáncer de Colon y Recto. Vol. 7. ???: ???; 2008.

  32. Ruiz Molina JM, Aceytuno RG, Rincón DG, et al. Cáncer de canal anal. Rev Gastroenterol Mex 1997;62:184-8.

  33. Cetina L, Rivera L, Hinojosa J, et al. Routine management of locally advanced cervical cancer with concurrent radiation and cisplatin. Five-year results. BMC Womens Health. 2006;6:3.

  34. De Santis M, Bachner M, Cerveny M, et al. Combined chemoradiotherapy with gemcitabine in patients with locally advanced inoperable transitional cell carcinoma of the urinary bladder and/or in patients ineligible for surgery: a phase I trial. Ann Oncol. 2014;25:1789-94.

  35. Allegra CJ, Yothers G, O’Connell MJ, et al. Neoadjuvant 5-FU or capecitabine plus radiation with or without oxaliplatin in rectal cancer patients: a phase III randomized clinical trial. J Natl Cancer Inst. 2015;107:1-8.

  36. James RD, Glynne-Jones R, Meadows HM, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2×2 factorial trial. Lancet Oncol. 2013;14:516-524.

  37. Olarte A, Cambeiro M, Moreno-Jiménez M, et al. Dose escalation with external beam radiation therapy and high-dose-rate brachytherapy combined with long-term androgen deprivation therapy in high and very high risk prostate cancer: comparison of two consecutive high-dose-rate schemes. Brachytherapy. 2016;15:127-35.

  38. Warde P, Mason M, Ding K, et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 2011;378: 2104-11.

  39. Wilkinson-Ryan I, Binder PS, Pourabolghasem S, et al. Concomitant chemotherapy and radiation for the treatment of advancedstage endometrial cancer. Gynecol Oncol. 2014;134:24-8.




2020     |     www.medigraphic.com